dc.contributor.author | Banerji, U | |
dc.contributor.author | Workman, P | |
dc.date.accessioned | 2016-10-19T16:37:51Z | |
dc.date.issued | 2016-08-01 | |
dc.identifier.citation | Seminars in oncology, 2016, 43 (4), pp. 436 - 445 | |
dc.identifier.issn | 0093-7754 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/181 | |
dc.identifier.eissn | 1532-8708 | |
dc.identifier.doi | 10.1053/j.seminoncol.2016.06.001 | |
dc.description.abstract | The Pharmacological Audit Trail (PhAT) comprises a set of critical questions that need to be asked during discovery and development of an anticancer drug. Key aspects include: (1) defining a patient population; (2) establishing pharmacokinetic characteristics; (3) providing evidence of target engagement, pathway modulation, and biological effect with proof of concept pharmacodynamic biomarkers; (4) determining intermediate biomarkers of response; (5) assessing tumor response; and (6) determining how to overcome resistance by combination or sequential therapy and new target/drug discovery. The questions asked in the PhAT should be viewed as a continuum and not used in isolation. Different drug development programmes derive different types of benefit from these questions. The PhAT is critical in making go-no-go decisions in the development of currently studied drugs and will continue to be relevant to discovery and development of future generations of anticancer agents. | |
dc.format | Print-Electronic | |
dc.format.extent | 436 - 445 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | W B SAUNDERS CO-ELSEVIER INC | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | DNA Damage | |
dc.subject | Neovascularization, Pathologic | |
dc.subject | Antineoplastic Agents | |
dc.subject | Positron-Emission Tomography | |
dc.subject | Treatment Outcome | |
dc.subject | Apoptosis | |
dc.subject | Cell Proliferation | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Patient Selection | |
dc.subject | Drug Discovery | |
dc.subject | Biomarkers, Tumor | |
dc.title | Critical parameters in targeted drug development: the pharmacological audit trail. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2015-10-23 | |
rioxxterms.versionofrecord | 10.1053/j.seminoncol.2016.06.001 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2016-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Seminars in oncology | |
pubs.issue | 4 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.publication-status | Published | |
pubs.volume | 43 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | |
icr.researchteam | Medicine Drug Development Unit (de Bono) | |
dc.contributor.icrauthor | Banerji, Udai | |
dc.contributor.icrauthor | Workman, Paul | |